Aurora Kinase A Inhibition: A Mega-Hit for Myelofibrosis Therapy?
Richard T PiszczatowskiUlrich SteidlPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
The positive but limited efficacy of JAK inhibitors has sparked the need for alternative therapeutic targets in the treatment of myelofibrosis. The discovery of novel targets, like Aurora Kinase A, may provide new avenues of single-agent and combinatorial therapy for myelofibrosis and restoration of normal bone marrow function.See related article by Gangat et al., p. 4898.